Cadence Pharmaceuticals, (FRA:QEW) Short-Term Debt & Capital Lease Obligation : €7.87 Mil (As of Dec. 2013)

View and export this data going back to . Start your Free Trial

What is Cadence Pharmaceuticals, Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Cadence Pharmaceuticals,'s Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2013 was €7.87 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Cadence Pharmaceuticals,'s Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2013 was €13.53 Mil.

Cadence Pharmaceuticals, Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Cadence Pharmaceuticals,'s Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadence Pharmaceuticals, Short-Term Debt & Capital Lease Obligation Chart

Cadence Pharmaceuticals, Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

4.42

3.04

7.87

Cadence Pharmaceuticals, Quarterly Data
	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															-	1.97	3.94	5.94	7.87

Cadence Pharmaceuticals, Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Cadence Pharmaceuticals, Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Cadence Pharmaceuticals,'s Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Cadence Pharmaceuticals, (FRA:QEW) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadence Pharmaceuticals, Inc. (FRA:QEW) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cadencepharm.com

Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. The Company's main activities are conducting research and development activities as well as conducting clinical trials. The company has in-licensed rights to products: Acetavance, an intravenous formulation of acetaminophen, and Omigard, an omiganan pentahydrochloride 1% aqueous gel. It in-licensed the exclusive United States, or U.S., and Canadian rights to Acetavance from Bristol-Myers Squibb Company, or BMS, which markets this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. The Company is developing Acetavance, a proprietary intravenous formulation of acetaminophen, for the U.S. market for the treatment of acute pain and fever in adults and children. In its oral form, acetaminophen is the most widely used drug for the treatment of pain and fever in the U.S. The Company's licensor, BMS, currently markets this proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the U.S, where it is known as paracetamol and is marketed under the brand name Perfalgan.

Cadence Pharmaceuticals, (FRA:QEW) Headlines

No Headlines